Drug concentration in inflamed periodontal tissues after systemically administered azithromycin

Journal of Periodontology

Volumn 78, Issue 5, 2007, Pages 918-923

  Gomi, Kazuhiro ^a,b   Yashima, Akihiro ^a   Iino, Fumiaki ^a   Kanazashi, Mikimoto ^a   Nagano, Takatoshi ^a   Shibukawa, Naoya ^a   Ohshima, Tomoko ^a   Maeda, Nobuko ^a   Arai, Takashi ^a  

^a TSURUMI UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Azithromycin; Bacteria; Inhibitory concentration; Oral administration; Periodontitis

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN;

ADULT; ARTICLE; CONNECTIVE TISSUE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PERIODONTITIS; PERIODONTIUM; TIME;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CONNECTIVE TISSUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERIODONTAL POCKET; PERIODONTIUM; TIME FACTORS;

EID: 33947681600     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2007.060246     Document Type: Article

References (41)

1. Socransky SS, Haffajee AD. Evidence of bacterial etiology: A historical perspective. Periodontol 2000 1994; 5:7-25.
2. Haffajee AD, Socransky SS. Microbial etiological agents of destructive periodontal diseases. Periodontol 2000 1994;5:78-111.
3. Listgarten MA. Structure of the microbial flora associated with periodontal health and disease in man. A light and electron microscopic study. J Periodontol 1976; 47:1-18.
4. Lindhe J, LiIjenberg B, Adielson B, Borjesson I. Use of metronidazole as a probe in the study of human periodontal disease. J Clin Periodontol 1983; 10: 100-112.
5. Smith BA. Metronidazole in periodontitis: Reduced need for surgery. J Clin Periodontol 1992; 19:103-112.
6. Loesche WJ, Schmidt E, Smith BA, Morrison EC, Caffesse R, Hujoel PP. Effects of metronidazole on periodontal treatment needs. J Periodontol 1991;62: 247-257.
7. Soder PO, Frithjof L, Wikner S, et al. The effect of systemic metronidazole after non-surgical treatment in moderate and advanced periodontitis in young adults. J Periodontol 1990;61:281-288.
8. Eisenberg L, Suchow R, Coles RS, Deasy MJ. The effects of metronidazole administration on clinical and microbiologic parameters of periodontal disease. Clin Prev Dent 1991;13:28-34.
9. Feres M, Haffajee AD, Goncalves C, et al. Systemic doxycycline administration in the treatment of periodontal infections. 1. Effect on the subgingival microbiota. J Clin Periodontol 1999;26:775-783.
10. Noyan U, Yilmaz S, Kuru B, Kadir T, Acar O, Buget E. A clinical and microbiological evaluation of systemic and local metronidazole delivery in adult periodontitis patients. J Clin Periodontol 1997;24:158-165.
11. van Winkelhoff AJ, Rams TE, Slots J. Systemic antibiotic therapy in periodontics. Periodontol 2000 1996; 10:45-78.
12. Lindhe J, LiIjenberg B. Treatment of localized juvenile periodontitis. Results after 5 years. J Clin Periodontol 1984;11:399-410.
13. Kornman KS, Robertson PB. Changes of subgingival total colony forming units and black pigmented bacteroides after a single irrigation of periodontal pockets with 1.64% SnF2. J Periodontol 1985;56:330-333.
14. Mandell RL, Socransky SS. Microbiological and clinical effects of surgery plus doxycycline on juvenile periodontitis. J Periodontol 1988;59:373-379.
15. Novak MJ, Stamatelakys C, Adair SM. Resolution of early lesions of juvenile periodontitis with tetracycline therapy alone: Long-term observations of 4 cases. J Periodontol 1991;62:628-633.
16. Fowler EB, Breault LG, Wolfgang M. Radiographic osseous regeneration after initial therapy with systemic doxycycline. Mil Med 2000; 165:796-799.
17. Slots J, Rams TE. Antibiotics in periodontal therapy: Advantages and disadvantages. J Clin Periodontol 1990; 17:479-493.
18. Gordon JM, Walker CB. Current status of systemic antibiotic usage in destructive periodontal disease. J Periodontol 1993;64:760-771.
19. Ellen RP, McCulloch CA. Evidence versus empiricism: Rational use of systemic antimicrobial agents for treatment of periodontitis. Periodontol 2000 1996; 10:29-44.
20. Nickel JC, Ruseska J, Wright JB, Costerton JW. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob Agents Chemother 1985;27:619-624.
21. Anwar H, Dasgupta M, Lam K, Costerton JW. Tobramycin resistance of mucoid Pseudomonas aeruginosa biofilm grown under iron limitation. J Antimicrob Chemother 1989;24:647-655.
22. Anwar H, Van Biesen T, Dasgupta M, Lam K, Costerton JW. Interaction of biofilm bacteria with antibiotics in a novel in vitro chemostat system. Antimicrob Agents Chemother 1989;33:1824-1826.
23. Hoyle BD, Costerton JW. Transient exposure to a physiologically-relevant concentration of calcium confers to bramycin resistance upon sessile cells of Pseudomonas aeruginosa. FEMS Microbiol Lett 1989;51:339-342.
24. Hoyle BD, Jass J, Costerton JW. The biofilm glycocalyx as a resistance factor. J Antimicrob Chemother 1990;26:1-6.
25. Brown MR, Allison DG, Gilbert P. Resistance of bacterial biofilm to antibiotics: A growth-rate related effect? J Antimicrob Chemother 1988;22:777-780.
26. Socransky SS, Haffajee AD, Ximenez-Fyvie LA, Feres M, Mager D. Ecological considerations in the treatment of Porphyromonas gingivalis periodontal infections. Periodontol 2000 1999;20:341-362.
27. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-282.
28. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissue. J Antimicrob Chemother 1990;25(Suppl. A):73-82.
29. McDonald PJ, Pruul H. Phagocytic uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis 1991;10:828-833.
30. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991;91:5-11.
31. Löe H, Silness J. Periodontal disease in pregnancy. I, Prevalence and severity. Acta Odontol Scand 1963; 21:533-551.
32. Ashimoto A, Chen C, Bakker I, Slots J. Polymerase chain reaction detection of 8 putative periodontal pathogens in subgingival plaque of gingivitis and advanced periodontitis lesions. Oral Microbiol Immunol 1996;11:266-273.
33. Satoda T. The new clinical point of view in medicine for dentistry at the 21st century. J Jap Assoc Dental Sci 2003;22:11-17.
34. Greenberg RN. Overview of patient compliance with medication dosing: A literature review. Clin Ther 1984; 6:592-599.
35. Ciancio SG, Mather ML, McMullen JA. An evaluation of minocycline in patients with periodontal disease. J Periodontol 1980;51:530-534.
36. Beckey NP, Parra D, Colon A. Retrospective evaluation of a potential interaction between azithromycin and warfarin in patients stabilized on warfarin. Pharmacotherapy 2000;20:1055-1059.
37. Wiese MD, Cosh DG. Raised INR with concurrent warfarin and azithromycin. Aust J Hosp Pharm 1999; 29:159-161.
38. Foster DR, Milan NL. Potential interaction between azithromycin and warfarin. Pharmacotherapy 1999;19: 902-908.
39. Sefton AM, Maskell JP, Beighton D, et al. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. J Clin Periodontol 1996;23:998-1003.
40. Smith SR, Foyle DM, Daniels J, et al. A double-blind placebo-controlled trial of azithromycin as an adjunct to non-surgical treatment of periodontitis in adults: Clinical results. J Clin Periodontol 2002;29:54-61.
41. Malizia T, Tejada MR, Ghelardi E, et al. Periodontal tissue disposition of azithromycin. J Periodontol 1997; 68:1206-1209.